Outcome
    Limited

    Citicoline (CDP-Choline) for Cerebral Infarction Volume

    Citicoline was studied extensively for acute ischemic stroke based on membrane-stabilizing mechanisms. The large ICTUS trial found no significant benefit on recovery. It remains reasonable for cognitive applications, but not for reducing infarct volume — emergency reperfusion therapy is what saves brain tissue.

    Overview

    Citicoline was studied extensively for acute ischemic stroke based on membrane-stabilizing mechanisms. The large ICTUS trial found no significant benefit on recovery. It remains reasonable for cognitive applications, but not for reducing infarct volume — emergency reperfusion therapy is what saves brain tissue.

    Verdict

    Insufficient evidence

    Citicoline showed neuroprotection promise, but a large trial found no benefit for limiting stroke damage.

    How It Works

    Provides choline and cytidine for phosphatidylcholine synthesis, theoretically stabilizing neuronal membranes during ischemia.

    Dosing & Protocol

    Typical dose

    Recommended dose
    Not recommended for stroke. Standard cognitive dosing (250–500 mg/day) has no established role in infarct volume.
    Expected timeframe
    Not applicable.

    Protocol

    studied dose
    Acute stroke trials used 500-2000 mg/day started within 24 hours of onset, by intravenous or oral route
    evidence note
    Verdict is insufficient - the large trials were negative and this is a hospital question, not a supplement one
    what happened
    Early studies suggested reduced infarct growth, but the pooled ICTUS trial and subsequent meta-analyses found no significant benefit on functional outcome or infarct volume. Standard cognitive dosing of 250-500 mg/day has no established role in infarct volume at all
    what to do instead
    Acute stroke care is time-critical: call emergency services immediately for sudden face, arm or speech symptoms. Thrombolysis and thrombectomy within the treatment window are what reduce infarct volume
    secondary prevention
    Blood pressure control, antiplatelet or anticoagulant therapy as prescribed, statins, smoking cessation

    Evidence

    Citicoline in acute ischemic stroke: A randomized controlled trial

    Score: 7/10
    2022
    rct

    et al

    We did not find any significant difference between the Citicoline or placebo arms with respect to either our primary or secondary outcomes.

    View source

    Safety

    Caveats

    Do not use in place of emergency stroke care. Act FAST on stroke symptoms — time to thrombolysis/thrombectomy determines outcome.

    Less likely to help if

    All acute stroke patients on the evidence available - the large randomised trials were neutral.

    Medical Disclaimer

    The information provided on this website is for educational and informational purposes only and is not intended as a substitute for professional medical advice, diagnosis, or treatment. Always seek the advice of your physician or other qualified health provider with any questions you may have regarding a medical condition or before starting any supplement regimen.

    Individual results may vary. The statements on this website have not been evaluated by the Food and Drug Administration. Products and information are not intended to diagnose, treat, cure, or prevent any disease.